IMPACT OF MATERNAL LORATADINE ADMINISTRATION ON HYPOSPADIAS INCIDENCE IN CHILDREN
Keywords
Abstract
The safety of antihistamines during pregnancy has been a topic of concern due to potential risks to fetal development. This study investigates the impact of maternal Loratadine administration on the incidence of hypospadias in offspring. Loratadine is a commonly used second-generation antihistamine prescribed for allergy relief, but its effects on fetal development, particularly regarding urogenital abnormalities, warrant further examination.
Using a cohort study design, we analyzed data from pregnant women who were prescribed Loratadine and compared it to a control group of women who did not use antihistamines. The primary outcome of interest was the incidence of hypospadias in the children born to these mothers. Data were collected from medical records, including prescription history, maternal health, and birth outcomes, across multiple healthcare facilities.
Our findings reveal that the incidence of hypospadias among offspring of mothers who used Loratadine during pregnancy is comparable to the general population. Statistical analysis indicated no significant increase in risk associated with Loratadine use. This suggests that Loratadine may not be a major contributing factor to the development of hypospadias. However, the study highlights the need for continued monitoring and research into the effects of various medications during pregnancy to ensure maternal and fetal safety.
While the study provides reassurance regarding the use of Loratadine, it underscores the importance of evaluating the safety profiles of medications prescribed during pregnancy. Future research should explore additional factors that may influence the risk of congenital anomalies and contribute to more comprehensive guidelines for medication use in pregnant women.